JP7041077B2 - リジン結合体化免疫グロブリン - Google Patents

リジン結合体化免疫グロブリン Download PDF

Info

Publication number
JP7041077B2
JP7041077B2 JP2018563925A JP2018563925A JP7041077B2 JP 7041077 B2 JP7041077 B2 JP 7041077B2 JP 2018563925 A JP2018563925 A JP 2018563925A JP 2018563925 A JP2018563925 A JP 2018563925A JP 7041077 B2 JP7041077 B2 JP 7041077B2
Authority
JP
Japan
Prior art keywords
immunoglobulin
amino acid
residue
antigen
binding portion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018563925A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019525897A (ja
JP2019525897A5 (enExample
Inventor
ジャレッド スピデル，
アール アルボーン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59315675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7041077(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JP2019525897A publication Critical patent/JP2019525897A/ja
Publication of JP2019525897A5 publication Critical patent/JP2019525897A5/ja
Application granted granted Critical
Publication of JP7041077B2 publication Critical patent/JP7041077B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/02—Aminoacyltransferases (2.3.2)
    • C12Y203/02013—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018563925A 2016-06-10 2017-06-12 リジン結合体化免疫グロブリン Active JP7041077B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662348410P 2016-06-10 2016-06-10
US62/348,410 2016-06-10
PCT/JP2017/021672 WO2017213267A1 (en) 2016-06-10 2017-06-12 Lysine conjugated immunoglobulins

Publications (3)

Publication Number Publication Date
JP2019525897A JP2019525897A (ja) 2019-09-12
JP2019525897A5 JP2019525897A5 (enExample) 2020-07-16
JP7041077B2 true JP7041077B2 (ja) 2022-03-23

Family

ID=59315675

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018563925A Active JP7041077B2 (ja) 2016-06-10 2017-06-12 リジン結合体化免疫グロブリン

Country Status (21)

Country Link
US (2) US10941431B2 (enExample)
EP (1) EP3468614A1 (enExample)
JP (1) JP7041077B2 (enExample)
KR (1) KR102538866B1 (enExample)
CN (1) CN109475642B (enExample)
AU (1) AU2017279352B2 (enExample)
BR (1) BR112018075253A2 (enExample)
CA (1) CA3026991A1 (enExample)
CL (1) CL2021003383A1 (enExample)
CO (1) CO2018013314A2 (enExample)
IL (1) IL263329B (enExample)
JO (1) JOP20180118A1 (enExample)
MX (1) MX419566B (enExample)
MY (1) MY202858A (enExample)
NZ (1) NZ748605A (enExample)
PE (1) PE20190340A1 (enExample)
PH (1) PH12018502594A1 (enExample)
RU (2) RU2762939C2 (enExample)
SG (1) SG11201810470XA (enExample)
UA (1) UA126799C2 (enExample)
WO (1) WO2017213267A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4032902A1 (en) 2015-12-18 2022-07-27 Eisai R&D Management Co., Ltd. C-terminal lysine conjugated immunoglobulins
SG11201810470XA (en) 2016-06-10 2018-12-28 Eisai R&D Man Co Ltd Lysine conjugated immunoglobulins
EP3966238A2 (en) * 2019-05-09 2022-03-16 Merus N.V. Variant domains for multimerizing proteins and separation thereof
GB201907093D0 (en) * 2019-05-20 2019-07-03 Ucl Business Plc Antibody functionalisation
CA3167317C (en) * 2020-02-12 2025-05-27 Eli Lilly And Company CRYSTALLIZATION OF ANTIBODIES OR ANTIGEN-BINDING FRAGMENTS
JP7664943B2 (ja) * 2020-03-25 2025-04-18 イーライ リリー アンド カンパニー 多重特異性結合タンパク質およびそれを開発する方法
MX2022014530A (es) 2020-05-20 2023-02-27 Janssen Biotech Inc Métodos para la conjugación específica del sitio de proteínas que contienen dominios fc glicosilados.
US20240173377A1 (en) * 2020-09-25 2024-05-30 Epivax, Inc. Retro - inverso regulatory t cell epitopes
WO2023026235A1 (en) * 2021-08-27 2023-03-02 Janssen Biotech, Inc. Anti-psma antibodies and uses thereof
CN117164701A (zh) * 2022-12-27 2023-12-05 优洛生物(上海)有限公司 一种经改造的抗体、其制备方法及其用途
IL322523A (en) 2023-02-28 2025-10-01 Eisai R&D Man Co Ltd Anti-PSMA antibodies, conjugates and methods of use
US20240337664A1 (en) * 2023-04-07 2024-10-10 Regeneron Pharmaceuticals, Inc. Characterization of crosslinking sites in antibody-drug conjugates
CN119375471A (zh) * 2023-07-26 2025-01-28 菲鹏生物股份有限公司 抗体和抗体缀合物及其用途
WO2025199464A1 (en) 2024-03-22 2025-09-25 Eisai R&D Management Co., Ltd. Anti-trop2 antibody-drug conjugates and methods of use
CN120779021A (zh) * 2024-04-08 2025-10-14 菲鹏生物股份有限公司 抗体缀合物及其用途
WO2026044149A2 (en) 2024-08-21 2026-02-26 Eisai R&D Management Co., Ltd. Synthesis of drug-linker combinations for antibody-drug conjugates
US20260139068A1 (en) 2024-08-21 2026-05-21 Eisai R&D Management Co., Ltd. Anti-cd73 antibodies, conjugates, and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150284713A1 (en) 2012-11-09 2015-10-08 Innate Pharma Recognition tags for tgase-mediated conjugation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
EP2033662B1 (en) 2004-01-21 2012-10-17 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
CA2813411C (en) * 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
WO2013176516A1 (ko) 2012-05-24 2013-11-28 한화케미칼 주식회사 트랜스글루타미나아제를 이용하여 제조한 항체-약물 결합체 및 이의 용도
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
KR20160042871A (ko) * 2013-06-21 2016-04-20 이나뜨 파르마, 에스.아. 폴리펩티드의 효소적 콘쥬게이션
KR20160040556A (ko) * 2013-07-11 2016-04-14 노파르티스 아게 미생물 트랜스글루타미나제를 사용한 리신-특이적 화학효소적 단백질 변형
US10195289B2 (en) * 2013-07-31 2019-02-05 Rinat Neuroscience Corp. Engineered polypeptide conjugates using transglutaminase
KR20190072663A (ko) 2014-04-25 2019-06-25 리나트 뉴로사이언스 코프. 약물이 고도로 로딩된 항체-약물 접합체
EP4032902A1 (en) 2015-12-18 2022-07-27 Eisai R&D Management Co., Ltd. C-terminal lysine conjugated immunoglobulins
SG11201810470XA (en) 2016-06-10 2018-12-28 Eisai R&D Man Co Ltd Lysine conjugated immunoglobulins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150284713A1 (en) 2012-11-09 2015-10-08 Innate Pharma Recognition tags for tgase-mediated conjugation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bioconjugate Chem.，2008年，Vol.19，p.271-278

Also Published As

Publication number Publication date
US20210171998A1 (en) 2021-06-10
AU2017279352B2 (en) 2024-07-25
JP2019525897A (ja) 2019-09-12
PE20190340A1 (es) 2019-03-07
US10941431B2 (en) 2021-03-09
IL263329B (en) 2022-05-01
US20180044711A1 (en) 2018-02-15
RU2018145507A (ru) 2020-07-10
CL2021003383A1 (es) 2022-08-19
RU2762939C2 (ru) 2021-12-24
RU2021136863A (ru) 2022-02-01
BR112018075253A2 (pt) 2019-04-30
JOP20180118A1 (ar) 2019-01-30
KR102538866B1 (ko) 2023-06-02
PH12018502594A1 (en) 2019-10-14
AU2017279352A1 (en) 2018-12-13
MX419566B (es) 2025-01-14
NZ748605A (en) 2023-05-26
SG11201810470XA (en) 2018-12-28
CA3026991A1 (en) 2017-12-14
RU2018145507A3 (enExample) 2020-10-15
CN109475642B (zh) 2023-05-02
MY202858A (en) 2024-05-25
US11753669B2 (en) 2023-09-12
CO2018013314A2 (es) 2019-02-19
MX2018015331A (es) 2019-08-16
KR20190018159A (ko) 2019-02-21
CN109475642A (zh) 2019-03-15
IL263329A (en) 2018-12-31
WO2017213267A1 (en) 2017-12-14
EP3468614A1 (en) 2019-04-17
UA126799C2 (uk) 2023-02-08

Similar Documents

Publication Publication Date Title
US12214050B2 (en) C-terminal lysine conjugated immunoglobulins
US11753669B2 (en) Lysine conjugated immunoglobulins
EP3240573B1 (en) Enzymatic conjugation of polypeptides
CN113544155A (zh) 经修饰用于转谷氨酰胺酶缀合的抗体、其缀合物以及方法和用途
KR102861586B1 (ko) 글루타민-함유 경쇄 c-말단 연장부를 포함하는 항체, 그의 접합체, 및 방법 및 용도
CA3008645C (en) C-terminal lysine conjugated immunoglobulins
WO2025093562A1 (en) Antibody-drug conjugates having a tailor-made drug-to-antibody ratio
AU2022269007A1 (en) Methods and compositions thereof for site-specific labeling of human igg by proximity-based sortase-mediated ligation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200603

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220131

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220221

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220310

R150 Certificate of patent or registration of utility model

Ref document number: 7041077

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250